DUBLIN--(BUSINESS WIRE)--The "Asia-Pacific PDX Models Market - Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
Asia-Pacific PDX models market is estimated to grow with a healthy CAGR in the forecast period 2018 to 2025.
Prominent factors driving the growth of this market consist of rising number of pharmaceutical R&D activities in cancer research, advantages offered by PDX models offer compared with the classic approach, rising need for personalized medicine and increasing support for cancer research activities from government and non-government organization.
The Asia Pacific PDX models market is segmented based on type into two notable segments; mice models and rat models. In 2018, mice models segment is valued to rule with the highest market share 2025.
The Asia Pacific PDX models market is segmented in tumor type categories into six notable segments; respiratory tumor models, urological tumor models, gastrointestinal tumor models, hematological tumor models, gynecological tumor models and others. In 2018, respiratory tumor models segment is valued to rule with the highest market shares by 2025, rising at the highest CAGR.
The Asia Pacific PDX models market is segmented in application into preclinical drug development and oncology research and biomarker analysis. In 2018, preclinical drug development and oncology research segment is valued to rule with highest market shares and rising at the highest CAGR.
The Asia Pacific PDX models market is segmented in end user into contract research organization (CRO), academic and research institutions and pharmaceutical and biotechnology companies. In 2018, contract research organization (CRO) segment is valued to rule with highest market shares and rising at the highest CAGR.
Market Dynamics
Drivers
- Rising Number of Pharmaceutical R&D Activities in Cancer Research
- PDX Models Offer Advantages as Compared with the Classic Approach
- Rising Need for Personalized Medicine
- Increasing Support for Cancer Research Activities from Government & Non-Government Organization
Restraints
- High Cost of PDX Models
- Strict Regulation with Respect to the Utilization of Animal Models in Cancer Research
Opportunities
- Increasing Demand for Humanized PDX Models
Challenges
- Limitations of PDX Models
Companies Profiled
- Crown Bioscience Inc.
- The Jackson Laboratory
- Champion Oncology Inc.
- Charles River
- Oncodesign
- Wuxi AppTec
- Horizon Discovery Group PLC
- Pharmatest Services
- Hera Biolabs
- EPO Berlin-Buch GmbH
- Xentech
- Urolead
- Creative Animodel
- EUROPDX
- MI Bioresearch Inc.
- Aragen Bioscience
For more information about this report visit https://www.researchandmarkets.com/research/647q8g/asiapacific_pdx?w=4
